Merck

Merck to Leverage BigHat's AI Platform in 3 Drug Discovery Programs
Merck to Leverage BigHat's AI Platform in 3 Drug Discovery Programs
BioSpace
Merck
BigHat Biosciences
R&D
artificial intelligence
Flag link:
Merck scores another win for Keytruda, this time in HER2-negative cancer
Merck scores another win for Keytruda, this time in HER2-negative cancer
Endpoints
Merck
Keytruda
clinical trials
adenocarcinoma
Flag link:
Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis
Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis
Fierce Biotech
Merck
M&A
Imago BioSciences
blood cancer
Flag link:
Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
Sotatercept- the breakthrough PAH has been waiting for?
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Merck
sotatercept
Acceleron
PAH
Flag link:
Is Merck Too Dependent on Keytruda?
Is Merck Too Dependent on Keytruda?
Motley Fool
Merck
Keytruda
Flag link:
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Flag link:
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Flag link:
A timeline of Ken Frazier’s tenure at Merck
A timeline of Ken Frazier’s tenure at Merck
Medical Marketing and Media
Kenneth Frazier
Merck
Pharma CEOs
Flag link:
Merck CEO Rob Davis has business development on the brain as he builds 'pipeline of the future'
Merck CEO Rob Davis has business development on the brain as he builds 'pipeline of the future'
Endpoints
Merck
Rob Davis
Pharma CEOs
M&A
Flag link:
Kenneth Frazier announces retirement after decades at Merck
Kenneth Frazier announces retirement after decades at Merck
Medical Marketing and Media
Merck
Kenneth Frazier
Pharma CEOs
Flag link:
Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost
Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost
TheStreet.com
Merck
earnings
Flag link:
MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference
MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference
BioSpace
Merck
Biogen
Bristol Myers Squibb
MS
multiple sclerosis
ECTRIMS
Flag link:
Is Merck Moving Toward Another Blockbuster Drug Launch?
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool
Merck
sotatercept
PAH
Flag link:
Merck fined $38M in Spain for hindering generic competition for NuvaRing
Merck fined $38M in Spain for hindering generic competition for NuvaRing
Fierce Pharma
Merck
Spain
anti-competitive scheme
Flag link:
Merck tees up Prevymis filing in kidney transplant recipients after phase 3 trial win
Merck tees up Prevymis filing in kidney transplant recipients after phase 3 trial win
Fierce Pharma
Merck
Prevymis
kidney transplants
clinical trials
CMV
IDWeek
Flag link:
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Flag link:
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Fierce Biotech
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration
Flag link:
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
BioSpace
Kineta
Merck
Keytruda
anti-VISTA
monoclonal antibodies
solid tumors
Flag link:
Few safe havens surface in another down quarter for biopharma
Few safe havens surface in another down quarter for biopharma
EP Vantage
biopharma stocks
COVID-19
Eli Lilly
Bristol Myers Squibb
Merck
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Neurocrine
Sarepta Therapeutics
Orion
Pfizer
GSK
Roche
Moderna Therapeutics
BeiGene
BioNTech
Novavax
CureVac
Flag link:

Pages